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the trends for cemented and uncemented fixation technique until 2021 by linear
regression. A dynamic Markov model with a cycle length of one year and time
frame of 10 years was developed to calculate the number of revisions and costs
from a hospital resource-use perspective. Patients enter the model after primary
THA and can progress to septic or aseptic revision and death. The transmission
probabilities were derived from Scandinavian registry studies. Hospital costs were
taken from published literature about resource utilization in England and were
discounted by 3% annually. RESULTS: An annual increase of 3,960 THAs (R-square,
0,87) was observed during the period. The share of uncemented THAs increased
from 20,2% in 2004 to 42,2% in 2008 with an annual increase of 3,707 uncemented
THAs (R-square, 0,99). The proportion of cemented THAs decreased steadily. A
continuation of this trend would lead to hospital costs of £7,246 million and 16193
revisions over a 10 year period. A reversal of this trendwould lead to costs of £7,176
million and 14980 revisions, resulting in savings of £69,8million and the avoidance
1212 revisions. CONCLUSIONS: The results suggest that the current trend towards
uncemented fixation of THAs is unjustified. A shift towards cemented fixation
technique should be considered.
PSU10
COST-EFFECTIVENESS OF PRIMARY PCI WITHOUT ONSITE SURGICAL BACKUP
Ramos P
University of Louisville, Louisville, KY, USA
OBJECTIVES: The American College of Cardiologists and the American Heart Asso-
ciation strongly recommend that a hospital performing PCI must also have coro-
nary artery bypass graft capabilities. Following these recommendations, the state
of Kentucky has limited the number of hospitals allowed to perform PCI and
thereby limiting access to this life-saving procedure. Recently, the state of Ken-
tucky evaluated if hospitalswithout such capabilities should be allowed to perform
primary PCI. The resulting data allowed the establishment of the medical sound-
ness of allowing such hospitals to perform primary PCI. The current study aims to
evaluate the financial feasibility of allowing these hospitals to do emergency PCI in
addition to hospitals with onsite open-heart surgery capabilities.METHODS: Esti-
mates have been derived from a systematic literature review of national studies
based on PCI registries as well as our earlier study - KENTUCKY PILOT PROJECT FOR
PRIMARY PCI WITHOUT ONSITE CABG. Costs estimates were derived from the Na-
tional Inpatient Sample. In determining costs, the observations were extracted by
filtering using ICD-9 codes using SAS. A deterministic model, implemented in Mi-
crosoft Excel, was developed so that more uncertainty would not be introduced.
The evaluation estimated the incremental cost effectiveness ratio (ICER) of allow-
ing regional hospitals to perform primary PCI from a payer’s perspective. Uncer-
tainty about the model parameters was investigated through sensitivity analysis.
RESULTS:The study found that therewere no statistically significant differences in
outcomes between hospitals with and without CABG capabilities. The only char-
acteristic, which was significantly different between these two groups, was total
charges. The alternative to allow Regional Hospitals as well to perform primary PCI
dominated the other alternative of Only Allowing Hospitals with Onsite CABG to per-
form PCI. CONCLUSIONS: States, such as Kentucky, that strictly follow the AHA/
ACC recommendations about PCI should consider the cost-effectiveness evidence
when making public policy.
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OBJECTIVES: To estimate the impact of radiofrequency ablation (RFA) on short and
long-term healthcare utilization and expenditures in general and Medicare popu-
lations with AF.METHODS:We analyzed data from the USMarketScan® Commer-
cial Claims and Encounters Database and Medicare Supplemental Database from
Thomson Reuters. The databases are comprised of de-identified patient-level re-
cords from employer-sponsored and public health insurance plans. We used a
coding algorithm to identify 3,194 patients with an RFA procedure for treatment of
AF, who had continuous enrollment in the database 6 months prior to their first
ablation, and aminimumof one year follow-up post ablation. Multivariable regres-
sion models for utilization and expenditures were built for all patients, and sub-
analyses were performed for patients 65-years and over. Results are reported for
five samples, based on duration of available follow-up: 12 months, 18 months, 2
years, 2.5 years, and 3 years post ablation. RESULTS: Compared to the six months
prior to RFA, therewere significant reductions in the number of outpatient appoint-
ments, hospital inpatient days, and emergency room visits in the total study pop-
ulation as well as the subset of patients 65 and older. There was a statistically
significant (p.01) decrease in total expenditures (insurer and patient out-of-
pocket expenditures) across all five time periods, with average savings of approx-
imately $5,000 over each six month period after ablation ($800 per month). For
patients 65 and over, the average savings were approximately $700 per month.
Drug utilization also significantly declined (p.05), with average savings in
medication expenditures ranging from $317 to $578 per 6 month period. The
reduction in drug utilization was durable and significant in patients 65 and over.
CONCLUSIONS: RFA for AF reduces real-world healthcare utilization and expendi-
tures up to 3 years post ablation. This reductionwas consistent, significant, andhas
implications for both general and Medicare populations.
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OBJECTIVES: Non-adherence to medication regimens after organ transplantation
is a major risk factor for acute rejection and graft loss, however, there is limited
data quantifying the associated risk. This study examines the association between
adherence to immunosuppressant therapy and rejection in liver and kidney organ
transplant recipients. METHODS: This is a randomized, cross sectional analysis.
Adherence to immunosuppressants was assessed by administering the Immuno-
suppresive Therapy Adherence Scale (ITAS) to patients at the time of their clinic
appointment. Rejection was defined as biopsy proven rejection. The number of
biopsies, number of rejections, rejection severity and length of hospital stay due to
rejection were collected. Immunosuppressant regimens, levels, number of dose
changes, and number of tablets/capsules per day were obtained. Logistic regres-
sion model was used to determine the association between rejection and adher-
ence, gender and number of tablets/capsules consumed per day. RESULTS: A total
of 67 patients were included in this study, from which 21(31%) were males with an
average age of 51 years, SD11.6. There were 49 (73.1%) kidney recipients, 14
(20.9%) liver recipients and 4 (5.9%) combination. At least one rejection was ob-
served in 26 (38.8%) of the patients, from which 18 (69.2%), 6 (23.1%) and 2 (7.7%)
were kidney, liver and combination, respectively. A total of 35 (52.3%) of the pa-
tients were found to be non-adherent with their medications, from which 18
(51.4%) had at least one rejection. Patients were taking an average of 18 tablets/
capsules per day. The logistic regression showed that gender and tablets/capsules
consumed per day had no impact on rejection, however, non-adherence is signif-
icantly associated with rejection (OR0.264, 95% CI is 0.089-0.784). Non adherent
patient are 74% more likely to have a rejection compared to adherent patients.
CONCLUSIONS: Non-adherence to immunosuppressive medication results in in-
creased rejection rates in kidney and liver transplant recipients.
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OBJECTIVES: Significant health risks impact on individuals with morbid obesity
including deleterious effects on health related quality of life (HRQOL). A mono-
centric prospective studywas conducted to evaluate the impact of bariatric surgery
and morbid obesity on HRQOL. METHODS: Data were collected from 236 partici-
pants: 83 patients who were under consideration for bariatric surgery, 68 patients
who already have had a bariatric procedure and 85 volunteers. Participants were
asked to complete Bariatric and Obesity Specific Survey (BOSS), Short Form Health
survey (SF-36), Hospital Anxiety and Depression (HADS) scale, Moorehead-Ardelt
Quality of life Questionnaire (M-A QoLQ II), and a demographic data sheet.
RESULTS: Obese people displayed lower levels of HRQOL compared to non-obese
people with an almost linear negative relationship between bodymass index (BMI)
and HRQOL. Obese females with BMI between 30 and 40 were more susceptible to
the adverse effects of obesity compared to males, particularly in the domains of
“Incapacity” and “Sexual Health”. There was no statistically significant HRQOL
difference, however, between men and women in the non obese (BMI  30) and
morbid obesity (BMI 40). “Appearance and Health” and “Sexual Health” domains
were comparable between patients who had surgery and the control group.
CONCLUSIONS: Females are more susceptible to the adverse effects of weight
compared tomales up to certainweight level afterwhich gender equity in adversity
becomes the norm. The domains of “Appearance and Health” and “Sexual Health”
are the quickest domains that will recover from the negative impact of obesity
following bariatric surgery.
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OBJECTIVES: Studies on health-related quality of life (HRQoL) of patients on kidney
transplant waiting list remained scarce despite the fact that it can predict future
morbidity andmortality. The aims of the studywere therefore tomeasure theHRQoL
of patients on kidney transplant waiting list compared with that of the general popu-
lation, to identify non-disease factorswhich could impact on theHRQoL scores and to
evaluate the reliability of the SF-36 in this group of patients.METHODS: This was a
cross-sectional study of kidney transplant waiting list patients managed at a ter-
tiary renal unit in Singapore using the SF-36. A SF-36 normative calculator gener-
ated HRQoL scores for a matched cohort of the Singapore general population. Re-
liability of SF-36 was assessed by Cronbach’s alpha coefficients. RESULTS: There
were 265 respondents. Our study shows that HRQoL scores for patients on kidney
transplant waiting list were lower than the population norms across all subscales
and were clinically significant for General Health, Role Physical, Bodily Pain, Social
Functioning and Mental Component Summary scores. Non-disease factors like
being Chinese, married, employed, undergoing haemodialysis and not being of-
fered a living kidney donation predicted better HRQoL scores after adjusting for
possible confounders. Age, gender, educational level, household income, history of
kidney transplant, duration on transplant waiting list and years on dialysis did not
significantly influence SF-36 across all subscales scores. Seven of 8 subscales in
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